SLAMF7 (Signaling lymphocyte activation molecule family member 7), previously known as CS1 (CD2 subset 1), is a cell surface glycoprotein with high expression on malignant plasma cells in most MM patients. Here, SLAMF7 is linked to Miyoshi myopathy.